NC-CHILTERN/IDA
Chiltern , a leading global contract research organization, has acquired Integrated Development Associates Co. Ltd. (IDA), a CRO specializing in integrating Japan and Asia into global drug development.
With staff based in Japan, Korea and Southeast Asia, IDA has extensive expertise in establishing regulatory and development pathways for Japan and implementing Pan Asian clinical trials to achieve both Japanese and global regulatory objectives. IDA’s experience in a broad range of therapeutic areas and its local knowledge and relationships will allow Chiltern to offer optimal approaches for integrating Japan and Asia into global drug development. In addition, the acquisition opens opportunities for Japanese companies to enter a wider market by relying on Chiltern’s global expertise and connections.
“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” said Jim Esinhart, Ph.D. , Chiltern CEO. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”
IDA will do business as a wholly owned subsidiary of Chiltern and be renamed IDA, a Chiltern Company. As a part of this agreement, IDA’s founder and CEO, John Winebarger , will continue to lead IDA. Winebarger has more than 30 years’ experience working in Japan and will join Chiltern’s leadership team.
To learn more about Chiltern’s global clinical development services, visit Chiltern.com .
About Chiltern
Chiltern, a global contract research
organization, is a leading provider of clinical services and solutions
in a variety of therapeutic areas with engagement models for
biopharmaceutical and medical device industries. Chiltern’s team of more
than 4,300, located across 47 countries, provides comprehensive Clinical
Development, Medical & Scientific Affairs, Data & Analysis,
Pharmacovigilance and Strategic Regulatory services using a
collaborative approach for more efficient clinical trials. Visit Chiltern.com
to learn more about how Chiltern is Designed Around You®
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005368/en/
Contact:
SCORR Marketing for Chiltern
Lea Studer, +1-308-237-5567
lea@scorrmarketing.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 06:01:00 CEST | Press release
Michelob ULTRA Moves Into Top 5 Most Valuable Beer Brands GloballyAB InBev Brands Represent 8 of the Top 10 Most Valuable Beer Brands Globally Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuab
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 06:00:00 CEST | Press release
Awards honor B2B organizations that drive revenue growth through effective alignment of marketing, sales, and product strategies Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination crite
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom